DehydraTECH™ is technology for improved delivery of bioactive compounds.

Lexaria Bioscience Corp’s (NASDAQ:LEXX, LEXXW) proprietary drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier delivery methods and increasing the effectiveness of fat-soluble active molecules and drugs.

The Company’s technology can be applied to many different drugs and other active ingredients in oral formats including tablets, capsules, oral suspensions and more.


  • Increases bio-absorption
  • Reduces time of onset from up to 1 – 2 hours to just minutes
  • Masks unwanted tastes
  • Is much more effective at delivering drugs into the bloodstream
  • Provides a higher ratio of drug delivery expected to lower overall drug costs

Companies in various locations around the world are examining DehydraTECH for incorporation into a broad range of products. Lexaria operates a federally licensed, in-house research laboratory and is building a robust intellectual property portfolio with 46 patents granted internationally and many more patents pending worldwide.

About DehydraTECH

Lexaria’s patented DehydraTECH technology delivers these important benefits:

Lexaria’s disruptive DehydraTECH technology is available to be licensed to improve drug delivery for existing orally administered products or to create revolutionary new ones.

DehydraTECH Commercial Applications

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (i.e., fat-soluble) drug payloads. DehydraTECH is protected by 46 granted patents internationally and many more pending patents for use with a broad range of bioactive molecules, including but not limited to: solid-oral formats (i.e., pills, powder-filled capsules and dissolvable tablets), consumable liquid formats (i.e., oral suspensions, etc.) and even topical dosage forms (i.e., creams, lotions, balms, etc.).



Antiviral Drugs

Sign up to receive our news and updates